An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
Catalio Capital Management
Activity from announced rounds
- Rounds participated in
- 10
- Confirmed lead rounds
- 1 6 roles undisclosed
- New companies
- 10 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.2B 10 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
10 in this selectionBasecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.
Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Developing best-in-class radiopharmaceuticals for cancer treatment
AdvanCell develops targeted alpha radiopharmaceuticals for cancer using Lead-212, with integrated isotope supply and manufacturing.
AI-enabled virtual specialty care platform for managing high-cost chronic conditions
Develops treatments for patients suffering from thromboembolic disease
Provides non-CPAP alternative for Obstructive Sleep Apnea treatment
Develops medicines targeting historically undruggable protein targets in cancer